Exchange: OTC·Updated 09:30 AM EDT

ZVSAZyVersa Therapeutics Inc

$0.1948
$0.0297
(17.99%)
Today
EarningsAug 13
Mkt Cap$1.34M
Vol501.00
News
all
press releases
News Placeholder
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps
ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients.
Stocktwits
<
...
1
>
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.